Cargando…

Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure

BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Thanapirom, Kessarin, Teerasarntipan, Tongluk, Treeprasertsuk, Sombat, Choudhury, Ashok, Sahu, Manoj K., Maiwall, Rakhi, Pamecha, Viniyendra, Moreau, Richard, Al Mahtab, Mamun, Chawla, Yogesh Kumar, Devarbhavi, Harshad, Yu, Chen, Ning, Qin, Amarapurkar, Deepak, Eapen, Chundamannil E., Hamid, Saeed Sadiq, Butt, Amna Subhan, Kim, Dong Joon, Lee, Guan H., Sood, Ajit, Lesmana, Laurentious A., Abbas, Zaigham, Shiha, Gamal, Payawal, Diana A., Yuen, Man-Fung, Chan, Albert, Lau, George, Jia, Jidong, Rahman, Salimur, Sharma, Barjesh C., Yokosuka, Osamu, Sarin, Shiv Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844167/
https://www.ncbi.nlm.nih.gov/pubmed/34822057
http://dx.doi.org/10.1007/s12072-021-10266-8
_version_ 1784651421301342208
author Thanapirom, Kessarin
Teerasarntipan, Tongluk
Treeprasertsuk, Sombat
Choudhury, Ashok
Sahu, Manoj K.
Maiwall, Rakhi
Pamecha, Viniyendra
Moreau, Richard
Al Mahtab, Mamun
Chawla, Yogesh Kumar
Devarbhavi, Harshad
Yu, Chen
Ning, Qin
Amarapurkar, Deepak
Eapen, Chundamannil E.
Hamid, Saeed Sadiq
Butt, Amna Subhan
Kim, Dong Joon
Lee, Guan H.
Sood, Ajit
Lesmana, Laurentious A.
Abbas, Zaigham
Shiha, Gamal
Payawal, Diana A.
Yuen, Man-Fung
Chan, Albert
Lau, George
Jia, Jidong
Rahman, Salimur
Sharma, Barjesh C.
Yokosuka, Osamu
Sarin, Shiv Kumar
author_facet Thanapirom, Kessarin
Teerasarntipan, Tongluk
Treeprasertsuk, Sombat
Choudhury, Ashok
Sahu, Manoj K.
Maiwall, Rakhi
Pamecha, Viniyendra
Moreau, Richard
Al Mahtab, Mamun
Chawla, Yogesh Kumar
Devarbhavi, Harshad
Yu, Chen
Ning, Qin
Amarapurkar, Deepak
Eapen, Chundamannil E.
Hamid, Saeed Sadiq
Butt, Amna Subhan
Kim, Dong Joon
Lee, Guan H.
Sood, Ajit
Lesmana, Laurentious A.
Abbas, Zaigham
Shiha, Gamal
Payawal, Diana A.
Yuen, Man-Fung
Chan, Albert
Lau, George
Jia, Jidong
Rahman, Salimur
Sharma, Barjesh C.
Yokosuka, Osamu
Sarin, Shiv Kumar
author_sort Thanapirom, Kessarin
collection PubMed
description BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. METHODS: A total of 1,621 patients were prospectively enrolled and 637 (39.3%) of these patients had cirrhosis. Baseline characteristics, complications and mortality were compared between patients with and without cirrhosis. RESULTS: Alcohol consumption was more common in cirrhosis than non-cirrhosis (66.4% vs. 44.2%, p < 0.0001), while non-alcoholic fatty liver disease/cryptogenic CLD (10.9% vs 5.8%, p < 0.0001) and chronic HBV reactivation (18.8% vs 11.8%, p < 0.0001) were more common in non-cirrhosis. Only 0.8% of patients underwent liver transplantation. Overall, 28-day and 90-day mortality rates were 39.3% and 49.9%, respectively. Patients with cirrhosis had a greater chance of survival compared to those without cirrhosis both at 28-day (HR = 0.48; 95% CI 0.36–0.63, p < 0.0001) and 90-day (HR = 0.56; 95% CI 0.43–0.72, p < 0.0001), respectively. In alcohol CLD, non-cirrhosis patients had a higher 28-day (49.9% vs. 23.6%, p < 0.001) and 90-day (58.4% vs. 35.2%, p < 0.001) mortality rate than cirrhosis patients. ACLF patients with cirrhosis had longer mean survival than non-cirrhosis patients (25.5 vs. 18.8 days at 28-day and 65.2 vs. 41.2 days at 90-day). Exaggerated systemic inflammation might be the reason why non-cirrhosis patients had a poorer prognosis than those with cirrhosis after ACLF had occurred. CONCLUSIONS: The 28-day and 90-day mortality rates of ACLF patients without cirrhosis were significantly higher than those with cirrhosis in alcoholic CLD. The presence of cirrhosis and its stage should be evaluated at baseline to guide for management. Thai Clinical Trials Registry, TCTR20191226002. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10266-8.
format Online
Article
Text
id pubmed-8844167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-88441672022-02-23 Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure Thanapirom, Kessarin Teerasarntipan, Tongluk Treeprasertsuk, Sombat Choudhury, Ashok Sahu, Manoj K. Maiwall, Rakhi Pamecha, Viniyendra Moreau, Richard Al Mahtab, Mamun Chawla, Yogesh Kumar Devarbhavi, Harshad Yu, Chen Ning, Qin Amarapurkar, Deepak Eapen, Chundamannil E. Hamid, Saeed Sadiq Butt, Amna Subhan Kim, Dong Joon Lee, Guan H. Sood, Ajit Lesmana, Laurentious A. Abbas, Zaigham Shiha, Gamal Payawal, Diana A. Yuen, Man-Fung Chan, Albert Lau, George Jia, Jidong Rahman, Salimur Sharma, Barjesh C. Yokosuka, Osamu Sarin, Shiv Kumar Hepatol Int Original Article BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is considered a main prognostic event in patients with chronic liver disease (CLD). We analyzed the 28-day and 90-day mortality in ACLF patients with or without underlying cirrhosis enrolled in the ACLF Research Consortium (AARC) database. METHODS: A total of 1,621 patients were prospectively enrolled and 637 (39.3%) of these patients had cirrhosis. Baseline characteristics, complications and mortality were compared between patients with and without cirrhosis. RESULTS: Alcohol consumption was more common in cirrhosis than non-cirrhosis (66.4% vs. 44.2%, p < 0.0001), while non-alcoholic fatty liver disease/cryptogenic CLD (10.9% vs 5.8%, p < 0.0001) and chronic HBV reactivation (18.8% vs 11.8%, p < 0.0001) were more common in non-cirrhosis. Only 0.8% of patients underwent liver transplantation. Overall, 28-day and 90-day mortality rates were 39.3% and 49.9%, respectively. Patients with cirrhosis had a greater chance of survival compared to those without cirrhosis both at 28-day (HR = 0.48; 95% CI 0.36–0.63, p < 0.0001) and 90-day (HR = 0.56; 95% CI 0.43–0.72, p < 0.0001), respectively. In alcohol CLD, non-cirrhosis patients had a higher 28-day (49.9% vs. 23.6%, p < 0.001) and 90-day (58.4% vs. 35.2%, p < 0.001) mortality rate than cirrhosis patients. ACLF patients with cirrhosis had longer mean survival than non-cirrhosis patients (25.5 vs. 18.8 days at 28-day and 65.2 vs. 41.2 days at 90-day). Exaggerated systemic inflammation might be the reason why non-cirrhosis patients had a poorer prognosis than those with cirrhosis after ACLF had occurred. CONCLUSIONS: The 28-day and 90-day mortality rates of ACLF patients without cirrhosis were significantly higher than those with cirrhosis in alcoholic CLD. The presence of cirrhosis and its stage should be evaluated at baseline to guide for management. Thai Clinical Trials Registry, TCTR20191226002. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10266-8. Springer India 2021-11-25 /pmc/articles/PMC8844167/ /pubmed/34822057 http://dx.doi.org/10.1007/s12072-021-10266-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Thanapirom, Kessarin
Teerasarntipan, Tongluk
Treeprasertsuk, Sombat
Choudhury, Ashok
Sahu, Manoj K.
Maiwall, Rakhi
Pamecha, Viniyendra
Moreau, Richard
Al Mahtab, Mamun
Chawla, Yogesh Kumar
Devarbhavi, Harshad
Yu, Chen
Ning, Qin
Amarapurkar, Deepak
Eapen, Chundamannil E.
Hamid, Saeed Sadiq
Butt, Amna Subhan
Kim, Dong Joon
Lee, Guan H.
Sood, Ajit
Lesmana, Laurentious A.
Abbas, Zaigham
Shiha, Gamal
Payawal, Diana A.
Yuen, Man-Fung
Chan, Albert
Lau, George
Jia, Jidong
Rahman, Salimur
Sharma, Barjesh C.
Yokosuka, Osamu
Sarin, Shiv Kumar
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title_full Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title_fullStr Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title_full_unstemmed Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title_short Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
title_sort impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844167/
https://www.ncbi.nlm.nih.gov/pubmed/34822057
http://dx.doi.org/10.1007/s12072-021-10266-8
work_keys_str_mv AT thanapiromkessarin impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT teerasarntipantongluk impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT treeprasertsuksombat impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT choudhuryashok impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT sahumanojk impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT maiwallrakhi impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT pamechaviniyendra impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT moreaurichard impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT almahtabmamun impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT chawlayogeshkumar impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT devarbhaviharshad impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT yuchen impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT ningqin impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT amarapurkardeepak impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT eapenchundamannile impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT hamidsaeedsadiq impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT buttamnasubhan impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT kimdongjoon impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT leeguanh impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT soodajit impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT lesmanalaurentiousa impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT abbaszaigham impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT shihagamal impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT payawaldianaa impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT yuenmanfung impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT chanalbert impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT laugeorge impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT jiajidong impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT rahmansalimur impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT sharmabarjeshc impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT yokosukaosamu impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT sarinshivkumar impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure
AT impactofcompensatedcirrhosisonsurvivalinpatientswithacuteonchronicliverfailure